How allergy antibodies drive eczema itch
Regulation of IgE and Atopic Itch
Looks at whether changes in the sugar coating on allergy antibodies (IgE) make them more likely to cause itching in people with atopic dermatitis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11134592 on NIH RePORTER |
What this research studies
Researchers are exploring how changes to the sugar coating (glycosylation) of IgE antibodies affect allergic itch in atopic dermatitis. They will compare IgE from people who have eczema flares to IgE from controls and measure how these antibodies activate basophils and mast cells and trigger itch mediators like histamine and leukotriene C4. The work combines patient blood samples, laboratory cell studies, and mouse models to link antibody differences to itch behavior. The aim is to identify which antibody features and pathways drive flares so they can be targeted to reduce itching.
Who could benefit from this research
Good fit: People with atopic dermatitis (eczema), especially those with high IgE levels or who experience sudden worsening itch flares, are the most likely candidates.
Not a fit: People with non-allergic chronic itch or normal IgE levels may not benefit from findings that focus on IgE-driven mechanisms.
Why it matters
Potential benefit: Could lead to new ways to reduce eczema itch by targeting IgE sugars or the basophil/mast cell pathways they trigger.
How similar studies have performed: Prior lab studies, including work from this group, have shown that IgE glycosylation can change immune cell activation and link to itch in mice and early human samples, but translating this into treatments is still novel.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Conroy, Michelle E — Massachusetts General Hospital
- Study coordinator: Conroy, Michelle E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.